The aim of our study was to evaluate the clinical efficacy of flutamide (Flu), when used alone, on the course of hirsutism and to assess its effect on hormonal secretion. Thirty-six hirsute women [11 patients were affected by polycystic ovarian syndrome (PCOs), and 25 were classified as having idiopathic hirsutism (IH)] were treated with Flu, 375 mg daily for a 4-month period. We found a marked clinical improvement in the degree of hirsutism in all patients. Testosterone and free testosterone fell significantly in both groups, while SHBG concentrations showed an increase in PCOs. In these patients, a reduction in androstenedione levels was also evident. Basal DHEAS concentrations showed a significant decrease only in PCO women. No significant modifications in gonadotropin response to LHRH nor in adrenal steroid response to ACTH stimulation were observed in 12 of the IH women before therapy and after the first month. Although the main action of flutamide is attributed to its peripheral antiandrogenic properties, the decrease in circulating androgen levels observed during treatment suggests that it can also modulate androgen production and/or metabolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF03347717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, Maharashtra, 400019, India.
Polycystic ovarian syndrome (PCOS) is one of the chief causes of infertility in women of reproductive age. Several drugs belonging to the oral contraceptive class have been approved for the treatment of PCOS. Nonetheless, the capability to target only a few symptoms of PCOS and fatal side effects are key hurdles to their use.
View Article and Find Full Text PDFDisproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database.
Int J Clin Pharm
February 2025
Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Nasahara 4-20-1, Takatsuki, Osaka, 569-1094, Japan.
Article Synopsis
- Flutamide and bicalutamide, two nonsteroidal anti-androgens, are linked to a higher risk of liver injury compared to other similar medications like enzalutamide, apalutamide, and darolutamide.
- A study analyzed data from over 142,000 male patients and found that steroid use significantly reduced the risk of liver injury from these drugs, with odds ratios indicating a protective effect.
- The findings suggest that while flutamide and bicalutamide pose a risk for liver injury, the concurrent use of steroids may alleviate some of this risk, highlighting a potential management strategy.
Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
Prostate
November 2024
Astellas Pharma Inc., Northbrook, Illinois, USA.
Article Synopsis
- The study investigates the real-world occurrence of adverse events (AEs) in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving various treatments, reflecting a gap between current recommendations and actual practice.
- Data was collected from a large claims review in the U.S. between January 2014 and June 2021, focusing on 10 common AEs that significantly affect patient outcomes.
- A total of 4,145 patients were analyzed, with different treatment groups including ADT alone, ADT with nonsteroidal anti-androgens, docetaxel, and androgen receptor pathway inhibitors, enabling a comparison of AEs across these groups.
Unraveling the anti-androgenic mechanism of tris(2,3-dibromopropyl) isocyanurate (TBC) via the non-classical testosterone pathway and steroidogenesis: Potential human reproductive health implications.
Chemosphere
September 2024
Department of Biopharmacy, Medical University of Lublin, Chodźki 4a, 20-093, Lublin, Poland; Department of Biochemistry and Toxicology, University of Life Sciences, Akademicka 13, 20-950, Lublin, Poland. Electronic address:
The decline in male reproductive health, characterized by diminishing sperm count and testosterone levels, has raised concerns about environmental influences, particularly endocrine-disrupting chemicals (EDCs). Tris(2,3-dibromopropyl)isocyanurate (TBC), a novel brominated flame retardant widely used in electronics, textiles, and furniture, has emerged as a significant environmental contaminant with potential reproductive health implications. In this study, we investigated the molecular mechanisms underlying TBC-induced reproductive toxicity, particularly focusing on its impact on steroidogenesis and androgen signaling pathways using the GC-1 spg cell line as an in vitro model.
View Article and Find Full Text PDFSafety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies.
J Clin Med
May 2024
Department of Dermatology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
Article Synopsis
- Female androgenetic alopecia (FAGA) is the most common type of hair loss in women, showing a patterned progression in hair thinning.
- Various oral treatments, including spironolactone and reduced androgen activity medications, can help manage FAGA, but concerns exist about their use in women with past gynecological cancers.
- A review indicates that spironolactone is generally safe for treating FAGA, even for high-risk patients, but more research is needed to determine the safety of other treatments for those with gynecologic cancer histories.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!